Hepatology
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Hepatic Steatosis and Low-Density Lipoprotein Cholesterol Response After Statin Initiation: A Prospective Cohort Analysis.
Clinical takeawayUse standard statin dosing in MASLD for cardiovascular prevention. Hepatic steatosis does not impair LDL-C response and should not prompt dose modification or additional monitoring adjustments.
What it foundHepatic steatosis (≥5% liver fat fraction) does not significantly impair LDL-C response to statins; observed differences were 0.097 mmol/L per month (months 0-3, p=0.231) and -0.037 mmol/L per month (months 3-12, p=0.141), neither clinically nor statistically significant.
ContextMASLD is strongly associated with dyslipidemia and cardiovascular mortality. The concern was that hepatic steatosis might impair statin efficacy through altered drug metabolism. This prospective cohort confirms that statin-induced LDL-C reduction is unaffected by hepatic steatosis status.
Reinforcessuggested applicable standard· AASLD, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease" (Rinella ME et al., Hepatology 2023;77(5):1797-1835). DOI 10.1097/HEP.0000000000000323, PMID 36727674.
Decision at stakeUse standard statin dosing in patients with hepatic steatosis and do not reduce dose based on steatosis alone
AASLD, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease" (Rinella ME et al., Hepatology 2023;77(5):1797-1835). DOI 10.1097/HEP.0000000000000323, PMID 36727674. · reviewed 2026-07-21 ↗Statins are safe and recommended in MASLD/MASH and compensated cirrhosis when indicated for cardiovascular risk reduction. Start per standard CV risk-based criteria with baseline LFTs; routine ALT monitoring on statin is not required and pre-existing transaminitis is not a contraindication. Hold or reduce only for clinically significant ALT elevation, severe muscle symptoms, or decompensated cirrhosis on an individualized basis.
Lau KC … Yip TC · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗